96 related articles for article (PubMed ID: 8515420)
1. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.
Zablocki JA; Miyano M; Garland RB; Pireh D; Schretzman L; Rao SN; Lindmark RJ; Panzer-Knodle SG; Nicholson NS; Taite BB
J Med Chem; 1993 Jun; 36(13):1811-9. PubMed ID: 8515420
[TBL] [Abstract][Full Text] [Related]
2. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor.
Zablocki JA; Miyano M; Rao SN; Panzer-Knodle S; Nicholson N; Feigen L
J Med Chem; 1992 Dec; 35(26):4914-7. PubMed ID: 1479591
[No Abstract] [Full Text] [Related]
3. Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents.
Bovy PR; Tjoeng FS; Rico JG; Rogers TE; Lindmark RJ; Zablocki JA; Garland RB; McMackins DE; Dayringer H; Tóth MV
Bioorg Med Chem; 1994 Sep; 2(9):881-95. PubMed ID: 7712124
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
[TBL] [Abstract][Full Text] [Related]
5. SC-49992--a potent and specific inhibitor of platelet aggregation.
Nicholson NS; Panzer-Knodle SG; King LW; Taite BB; Keller BT; Tjoeng FS; Engleman VW; Giorgio TD; Feigen LP
Thromb Res; 1994 Jun; 74(5):523-35. PubMed ID: 8085253
[TBL] [Abstract][Full Text] [Related]
6. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists.
Zablocki JA; Rico JG; Garland RB; Rogers TE; Williams K; Schretzman LA; Rao SA; Bovy PR; Tjoeng FS; Lindmark RJ
J Med Chem; 1995 Jun; 38(13):2378-94. PubMed ID: 7608903
[TBL] [Abstract][Full Text] [Related]
7. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.
Samanen J; Ali F; Romoff T; Calvo R; Sorenson E; Vasko J; Storer B; Berry D; Bennett D; Strohsacker M
J Med Chem; 1991 Oct; 34(10):3114-25. PubMed ID: 1920361
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight, non-peptide fibrinogen receptor antagonists.
Alig L; Edenhofer A; Hadváry P; Hürzeler M; Knopp D; Müller M; Steiner B; Trzeciak A; Weller T
J Med Chem; 1992 Nov; 35(23):4393-407. PubMed ID: 1447740
[TBL] [Abstract][Full Text] [Related]
9. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
[TBL] [Abstract][Full Text] [Related]
10. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid.
Krysko AA; Chugunov BM; Malovichko OL; Andronati SA; Kabanova TA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2004 Nov; 14(22):5533-5. PubMed ID: 15482918
[TBL] [Abstract][Full Text] [Related]
11. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.
Egbertson MS; Chang CT; Duggan ME; Gould RJ; Halczenko W; Hartman GD; Laswell WL; Lynch JJ; Lynch RJ; Manno PD
J Med Chem; 1994 Aug; 37(16):2537-51. PubMed ID: 8057299
[TBL] [Abstract][Full Text] [Related]
12. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
[TBL] [Abstract][Full Text] [Related]
13. Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation.
Panzer-Knodle S; Taite BB; Mehrotra DV; Nicholson NS; Feigen LP
J Pharmacol Toxicol Methods; 1993 Sep; 30(1):47-53. PubMed ID: 8241546
[TBL] [Abstract][Full Text] [Related]
14. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
Andronati SA; Karaseva TL; Krysko AA
Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
[TBL] [Abstract][Full Text] [Related]
15. Synthetic peptides inhibit the interaction of von Willebrand factor-platelet membrane glycoproteins.
Mohri H; Zimmerman TS; Ruggeri ZM
Peptides; 1993; 14(2):125-9. PubMed ID: 8483792
[TBL] [Abstract][Full Text] [Related]
16. A synthetic peptide with anti-platelet activity derived from a CDR of an anti-GPIIb-IIIa antibody.
Jarrin A; Andrieux A; Chapel A; Buchou T; Marguerie G
FEBS Lett; 1994 Nov; 354(2):169-72. PubMed ID: 7957919
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).
Nicholson NS; Panzer-Knodle SG; Salyers AK; Taite BB; King LW; Miyano M; Gorczynski RJ; Williams MH; Zupec ME; Tjoeng FS
J Pharmacol Exp Ther; 1991 Mar; 256(3):876-82. PubMed ID: 2005585
[TBL] [Abstract][Full Text] [Related]
18. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).
Du XP; Plow EF; Frelinger AL; O'Toole TE; Loftus JC; Ginsberg MH
Cell; 1991 May; 65(3):409-16. PubMed ID: 2018974
[TBL] [Abstract][Full Text] [Related]
19. [The structure-antiaggregative activity relationship in a series of Arg-Gly-Asp analogs].
Mel'nik OV; Martinovich VP; Golubovich VP
Bioorg Khim; 2006; 32(2):137-43. PubMed ID: 16637284
[TBL] [Abstract][Full Text] [Related]
20. A modified Arg-Asp-Val (RDV) peptide derived during the synthesis of Arg-Glu-Asp-Val (REDV), a tetrapeptide derived from an alternatively spliced site in fibronectin, inhibits the binding of fibrinogen, fibronectin, von Willebrand factor and vitronectin to activated platelets.
Chen CS; Papayannopoulos IA; Timmons S; Chou SH; Thiagarajan P
Biochim Biophys Acta; 1991 Oct; 1075(3):237-47. PubMed ID: 1720019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
